Tuesday February 19, 5:51 pm Eastern Time
Press Release
SOURCE: IDEC Pharmaceuticals Corporation
Zevalin Therapeutic Regimen Receives FDA Marketing Approval
First Radioimmunotherapy Approved by FDA
SAN DIEGO--(BW HealthWire)--Feb. 19, 2002--IDEC Pharmaceuticals Corporation (Nasdaq: IDPH - news) today announced that Zevalin(TM) (Ibritumomab Tiuxetan) has been approved for marketing by the U.S. Food and Drug Administration (FDA). Zevalin, as part of the Zevalin therapeutic regimen, is indicated for the treatment of relapsed or refractory low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL) including patients with Rituxan® (Rituximab) refractory follicular NHL. The Zevalin therapeutic regimen consists of Rituxan preceding Indium-111 Zevalin followed seven to nine days later by a second infusion of Rituxan prior to Yttrium-90 Zevalin. This is the first radioimmunotherapy to receive FDA approval. It is estimated that commercial shipments of Zevalin will begin within approximately 30 to 60 days. <snip>
Tuesday February 19, 4:30 pm Eastern Time
Press Release
SOURCE: Cephalon, Inc.
Cephalon, Inc. Reports 2001 Financial Results
Cephalon Records First Full Year of Profits from Operations; Raises Guidance for 2002
WEST CHESTER, Pa., Feb. 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH - news) today reported product sales of $226.1 million and diluted earnings per share, before certain charges and extraordinary items, of $0.19 for the full year 2001. For the fourth quarter ended December 31, 2001, the company reported product sales of $67.1 million and diluted earnings per share, before certain charges and extraordinary items, of $0.17.
``We are delighted to announce our first full year of profitability from operations,'' said Frank Baldino, Jr., Ph.D., Chairman of the Board and CEO of Cephalon. ``It is especially exciting to achieve profitability while our products are still in their early stages of growth. This presents us with an excellent opportunity to develop the full potential of these products and drive earnings growth going forward.''
For the year 2001, sales of PROVIGIL® (modafinil) Tablets (C-IV) were $150.3 million, sales of ACTIQ® (oral transmucosal fentanyl citrate) (C-II) were $51.2 million and sales of GABITRIL® (tiagabine hydrochloride) were $24.6 million. For the fourth quarter of 2001, sales of the three products were $39.7 million, $20.9 million, and $6.5 million, respectively. Cephalon recorded other revenues of $40.5 million for the year 2001, and $12.5 million in the fourth quarter 2001, which included revenue from Cephalon's marketing collaboration with Novartis Pharma in the United Kingdom and revenues from several research and development collaborations. <snip> |
